Agerbæk, Mette Ø.
Bang-Christensen, Sara R.
Yang, Ming-Hsin
Clausen, Thomas M.
Pereira, Marina A.
Sharma, Shreya
Ditlev, Sisse B.
Nielsen, Morten A.
Choudhary, Swati
Gustavsson, Tobias
Sorensen, Poul H.
Meyer, Tim
Propper, David
Shamash, Jonathan
Theander, Thor G.
Aicher, Alexandra
Daugaard, Mads
Heeschen, Christopher
Salanti, Ali
Article History
Received: 21 November 2017
Accepted: 26 July 2018
First Online: 16 August 2018
Change Date: 7 June 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-022-29351-z
Competing interests
: M.Ø.A., T.M.C., A.S., M.D., T.T., and M.A.N. are shareholders in VAR2 Pharmaceuticals holding the intellectual property rights to use rVAR2 for binding ofCS and to capture CTCs. The remaining authors declare no competing interests.